TSPO ligand PK11195 improves Alzheimer-related outcomes in aged female 3xTg-AD mice
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) pathogenesis is a multifactorial process that involves numerous pathways within the central nervous system. Thus, interventions that interact with several disease-related pathways may offer an increased opportunity for successful prevention and treatment of AD. Translocator protein 18 kD (TSPO) is a mitochondrial protein that is associated with regulation of many cellular processes including inflammation, steroid synthesis, apoptosis, and mitochondrial respiration. Although TSPO ligands have been shown to be protective in several neurodegenerative paradigms, little work has been done to assess their potential as treatments for AD. Female 3xTg-AD mice were administered the TSPO ligand PK11195 once weekly for 5 weeks beginning at an age 16 months, an age characterized by extensive β-amyloid pathology and behavioral impairments. Animals treated with PK11195 showed improvements in behavior and modest reductions of in both soluble and deposited β-amyloid. The finding that short-term PK11195 treatment was effective in improving both behavioral and pathological outcomes in a model of late-stage AD supports further investigation of TSPO ligands as potential therapeutics for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 1×
“TSPO has long been implicated as an important mediator of steroidogenesis in tissues including gonads, adrenal gland and brain (23, 24), though recent observations suggest that it may not be essential to the process (25) or may be more important during aging (26).”
BackgroundRupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., Groyer, G., Adams, D., & Schumacher, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3295 · Cited by 930 · cited 3×
“Because TSPO expression is upregulated in reactive glia, it has been used as an in vivo PET imaging marker of neuroinflammation (6).”
BackgroundMethodInfluentialHughes, R. N. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.06.006 · Cited by 641 · cited 1×
“Mice were assessed on spontaneous alternation behavior in the Y-maze, a test of attention towards novelty and spatial memory (16) that is dependent upon limbic system structures including the hippocampus (17), as previously described (13).”
MethodChen, Z., Jalabi, W., Shpargel, K. B., Farabaugh, K. T., Dutta, R., Yin, X., Kidd, G. J., Bergmann, C. C., Stohlman, S. A., & Trapp, B. D. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0730-12.2012 · Cited by 432
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects
Rupprecht, R., Rammes, G., Eser, D., Baghai, T. C., Schüle, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H. O., Chaperon, F., et al. (2009) · Science · doi:10.1126/science.1175055 · Cited by 328
Chakrabarty, P., Jansen‐West, K., Beccard, A., Ceballos‐Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., & Das, P. (2010) · The FASEB Journal · doi:10.1096/fj.09-141754 · Cited by 328
Translocator protein (18 kDa) is involved in the regulation of reactive gliosis
Veiga, S., Carrero, P., Pernia, O., Azcoitia, I., & Garcia‐Segura, L. M. (2007) · Glia · doi:10.1002/glia.20558 · Cited by 62 · cited 3×
“Like Ro5–4864, the TSPO ligand isoquinoline carboxamide (PK11195) previously has been shown to decrease microglial activation, inflammation, and cognitive deficits in response to several insults, including lipopolysaccharide (LPS) (10, 11).”
Background
Cited by
Gui, Y., Marks, J. D., Das, S., Hyman, B. T., & Serrano‐Pozo, A. (2020) · Brain Pathology · doi:10.1111/bpa.12763 · Cited by 126
In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
Tournier, B. B., Tsartsalis, S., Ceyzériat, K., Garibotto, V., & Millet, P. (2020) · Cells · doi:10.3390/cells9091941 · Cited by 79
“In this view, several preclinical studies have shown that the use of TSPO agonists or antagonists may have a protective effect in the context of Alzheimer’s disease [141,158,159].”
BackgroundHuang, Q., Wang, Y., Chen, S., & Liang, F. (2023) · Aging and disease · doi:10.14336/ad.2023.0807 · Cited by 62
Tournier, B. B., Tsartsalis, S., Rigaud, D., Fossey, C., Cailly, T., Fabis, F., Pham, T., Grégoire, M.-C., Kövari, E., Moulin-Sallanon, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.022 · Cited by 62
“in 16-month old 3xTgAD female mice sustains the idea that TSPO is not only a marker of AD but also an actor of the progression of the pathology (Christensen and Pike, 2018).”
Metadata
- Authors
- Christensen, A., & Pike, C. J.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 683
- Pages
- 7-12
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2808832680
- Cited by
- 40
- References
- 7
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.